|
業務類別
|
Drug Manufacturers - General |
|
業務概覽
|
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment. |
| 公司地址
| 1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133 |
| 電話號碼
| +1 786 432-9792 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.mirapharmaceuticals.com |
| 員工數量
| 2 |
| Mr. Erez Aminov |
Chairman of the Board and Chief Executive Officer |
美元 438.75K |
28/07/2026 |
| Mr. Andriy Mushak |
Fractional Chief Financial Officer |
-- |
08/06/2026 |
|
|
| Mr. Erez Aminov |
Chairman of the Board and Chief Executive Officer |
28/07/2026 |
| Dr. Matthew Paul Del Giudice, M.D. |
Independent Director |
28/07/2026 |
| Dr. Denil Nanji Shekhat, M.D. |
Independent Director |
28/07/2026 |
| Mr. Edward MacPherson |
Independent Director |
28/07/2026 |
| Mr. Matthew Pratt Whalen, C.P.A. |
Independent Director |
28/07/2026 |
|
|
|
|
